Compare
Quince Therapeutics, Inc. vs Humacyte, Inc. vs Acumen Pharmaceuticals, Inc. vs Fennec Pharmaceuticals Inc.
| Latest fiscal year | Quince Therapeutics, Inc. QNCX | Humacyte, Inc. HUMA | Acumen Pharmaceuticals, Inc. ABOS | Fennec Pharmaceuticals Inc. FENC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $2.04M | n/a | $44.64M |
| Revenue growth (YoY) | n/a | n/a | n/a | -6.1% |
| Gross margin | n/a | -376.1% (computed) | n/a | n/a |
| Operating margin | n/a | n/m | n/a | -14.1% |
| Net margin | n/a | n/m | n/a | -21.8% |
| Net income | -$83.98M | -$40.83M | -$121.33M | -$9.74M |
| EPS (Diluted) | -$1.68 | -$0.26 | -$2.00 | -$0.34 |
| Operating cash flow | -$41.42M | -$105.04M | -$115.54M | -$12.47M |
| Free cash flow | -$41.78M | -$105.93M | -$115.63M | n/a |
| Cash & equivalents | $5.81M | $50.50M | $53.99M | $36.79M |
| Total assets | $93.52M | $116.37M | $122.83M | $70.55M |
| Total liabilities | $129.24M | $113.26M | $52.40M | $35.08M |
| Shareholders' equity | -$35.71M | $3.11M | $70.43M | $35.47M |
| Return on year-end equity | n/a | n/m | -172.3% | -27.5% |
| Shares outstanding | 55.73M | 193.00M | 60.58M | 34.16M |
Revenue, most recent five fiscal years
| Fiscal year | Quince Therapeutics, Inc. | Humacyte, Inc. | Acumen Pharmaceuticals, Inc. | Fennec Pharmaceuticals Inc. |
|---|---|---|---|---|
| Latest | n/a | $2.04M Ended 2025-12-31 | n/a | $44.64M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | n/a | $47.54M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $21.25M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $1.53M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |